PDCD1 and neoplasm: To tackle this question, we treated four established transplantable tumor models syngeneic to C57BL/6 mice with 4 biweekly intraperitoneal (i.p.)administrations of anti-PD-1 mAb (clone RMP1–14) (Fig. 1a).